BioCardia, Inc. (NASDAQ:BCDA) Sees Significant Increase in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 109,500 shares, a growth of 26.9% from the October 31st total of 86,300 shares. Currently, 3.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 822,600 shares, the short-interest ratio is currently 0.1 days.

BioCardia Stock Down 3.0 %

Shares of BioCardia stock traded down $0.07 on Friday, hitting $2.28. 16,839 shares of the company traded hands, compared to its average volume of 287,053. The company has a 50-day moving average price of $2.47 and a 200 day moving average price of $3.08. BioCardia has a 12-month low of $1.84 and a 12-month high of $10.79. The company has a market cap of $10.44 million, a PE ratio of -0.54 and a beta of 1.28.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of BioCardia in a report on Thursday, November 14th.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.